GeneDx Names Mark Gardner President to Lead Its Next Phase of Scale and Growth

Former Quest Diagnostics leader joins to fuel operational and commercial execution

GeneDx (NASDAQ:WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced the appointment of Mark Gardner as President, effective June 15, 2026.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260616791724/en/